EIF2B4: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

Target Name: EIF2B4

NCBI ID: G8890

EIF2B4: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Developmental Disorders

The EIF2B4 protein is a member of the EIF2B family, which plays a critical role in the regulation of essential genes, including those involved in cell growth, metabolism, and signaling pathways. EIF2B4 has been shown to play a key role in the regulation of the global protein exchange rate (GPE), which is the rate at which proteins are synthesized and degraded in the cell. GPE is a critical factor that regulates the cell's ability to synthesize new proteins and remove damaged or unnecessary proteins, and is involved in a wide range of cellular processes, including cell growth, differentiation, and survival.

Recent studies have identified EIF2B4 as a potential drug target or biomarker for a variety of diseases, including cancer, neurodegenerative diseases, and developmental disorders. In this article, we will explore the biology of EIF2B4 and its potential as a drug target, as well as the current state of research in this field.

The EIF2B4 Protein

EIF2B4 is a 21-kDa protein that is expressed in most tissues of the body. It is characterized by a N-terminal transmembrane domain, a catalytic C-terminal region, and a C-terminal region that is involved in protein-protein interactions. EIF2B4 is involved in the regulation of protein synthesis and degradation, as well as the regulation of cell growth and differentiation.

One of the key functions of EIF2B4 is its role in the regulation of the global protein exchange rate (GPE). GPE is the rate at which proteins are synthesized and degraded in the cell, and is regulated by a complex interplay of factors, including the cell cycle, the endoplasmic reticulum (ER), and various signaling pathways. EIF2B4 is shown to play a key role in the regulation of GPE, by regulating the activity of several key enzymes involved in the GPE pathway.

In addition to its role in GPE regulation, EIF2B4 is also involved in the regulation of a variety of cellular processes, including cell growth, differentiation, and survival. For example, EIF2B4 has been shown to play a key role in the regulation of cell cycle progression, by regulating the activity of the cyclin D1 enzyme. This enzyme is involved in the regulation of the cell cycle, and is critical for the proper progression of the cell cycle through the G1, S, G2, and M phases.

EIF2B4 is also involved in the regulation of apoptosis, which is a critical process that helps the cell to remove damaged or unnecessary proteins and prepare for programmed cell death. EIF2B4 has been shown to play a key role in the regulation of apoptosis, by regulating the activity of several key enzymes involved in this process.

Potential Drug Target

The potential use of EIF2B4 as a drug target or biomarker is based on its involvement in a wide range of cellular processes, including GPE regulation, cell growth, differentiation, and apoptosis. Several studies have shown that EIF2B4 can be effectively targeted with small molecules, and that these treatments can have a variety of different effects on cellular processes, including the regulation of GPE, cell growth, and apoptosis.

One of the key challenges in the development of EIF2B4 as a drug target is the lack of understanding of its precise mechanism of action. While several studies have identified key interactions between EIF2B4 and its downstream targets, the precise details of these interactions are not yet fully understood. This lack of understanding can make it difficult to design effective small molecules that specifically target EIF2B4, and to determine the full extent of

Protein Name: Eukaryotic Translation Initiation Factor 2B Subunit Delta

Functions: Catalyzes the exchange of eukaryotic initiation factor 2-bound GDP for GTP

More Common Targets